DUBLIN, Dec. 11, 2019 /PRNewswire/ -- The "T-Cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-Cell, Tumor Infiltrating Lymphocytes), By Indication (Hematologic Malignancies, Solid Tumors), And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.

The global T-cell therapy market size is expected to reach USD 7.51 billion, expanding at a CAGR of 15.4% by 2026.

The landmark approvals of Yescarta and Kymriah have spurred unprecedented advancements in the market. The launch of these breakthrough therapies has bolstered cash inflow for innovation, thereby driving the growth.

Expansion of the market for T-cell therapy significantly relies on shifting preference from first-line stem cell transplants and chemotherapy to third-line CAR T-cell therapy. Moreover, the ever-expanding plethora of medical conditions for which the T cell therapies is projected to bode well for the market growth. Rise in oncological disorders is projected to drive interest as well as investments in the T-cell therapy market in near future.

In contrast with the small-molecule landscape, engineered T cells market landscape is distinguished by an extensive network that encompasses several entities marked by connections academically, financially, and via technology licensing. Research bodies, and manufacturers, and regulators engage in assessing the long-term efficacy and safety of therapies to ensure safe access to patients.

By far, the antigen challenge and linked toxicity concerns have impeded the development of CAR T therapies in non-hematological malignancies. Market players are applying a data-driven approach of exploring this space to mitigate the challenge and expand the usage of T-cell therapy in indication type such as brain cancer and melanoma.

Further key findings from the report suggest:

Key Topics Covered

Chapter 1 Research Methodology

Chapter 2 Executive Summary2.1 Competition Milieu2.2 Market Snapshot2.3 Segment Outlook

Chapter 3 Market Variables, Trends, & Scope3.1 Penetration & Growth Prospect Mapping for Therapy Type, 20183.2 T-Cell Therapy-Market Dynamics3.2.1 Market driver analysis3.2.1.1 Rising investment in adoptive T cell transfer approaches of disease treatment3.2.1.2 Growing competition among market players3.2.1.3 Approval of Kymriah and Yescarta across various countries3.2.1.4 Developments in CAR T-cell therapy for solid tumors3.2.1.5 Technological advancements in manufacturing process3.2.2 Market restraint analysis3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy3.2.2.2 High prices of therapies3.2.2.3 CAR T limitations3.2.3 Opportunity analysis3.2.3.1 Facility expansion for cell and gene therapies3.2.3.2 Rising global financings in gene and cell therapy arena3.2.3.3 Ongoing developments in viral & non-viral vector manufacturing arena3.3 Regulatory Landscape3.3.1 Current and potential future approvals3.3.2 Frameworks for risk mitigation and safety monitoring3.3.3 Regulatory framework, by geography3.3.3.1 U.S.3.3.3.2 Europe3.3.3.3 China3.3.3.4 Japan3.4 Pricing and Payment Models for Adoptive Cellular Therapies (ACT)3.4.1 Insurance coverage3.4.2 Value-based price benchmarks3.4.3 Alternate payment strategies3.5 Patent Landscape3.6 Deals, Funding's, Partnerships and Collaborations3.6.1 Licensing deals3.6.2 Merger & acquisition deals3.6.3 Collaboration & partnerships3.7 Pipeline Analysis3.7.1 Clinical trial landscape3.8 Geographic Mapping of Companies3.9 Competitive Landscape for CD19directed CART Therapies and Other T-cell therapies3.10 T-cell Therapy Market-SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)3.10.1 Political landscape3.10.2 Economic landscape3.10.3 Social landscape3.10.4 Technology landscape3.11 Industry Analysis-Porter's3.11.1 Supplier bargaining power3.11.2 Buyer bargaining power3.11.3 Substitution threat3.11.4 Threat from new entrant3.11.5 Competitive rivalry

Chapter 4 T-cell Therapy Market: Modality Estimates & Trend Analysis4.1 T-cell Therapy Market: Modality Movement Analysis4.2 Research4.3 Commercialized

Chapter 5 T-cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis5.1 T-cell Therapy Market: Therapy Type Movement Analysis5.2 CAR T-cell Therapy5.3 T Cell Receptor (TCR)-based5.4 Tumor Infiltrating Lymphocytes (TIL)-based

Chapter 6 T-cell Therapy Market Categorization: Indication Estimates & Trend Analysis6.1 T-cell Therapy Market: Indication Movement Analysis6.2 Hematologic Malignancies6.3 Solid Tumors

Chapter 7 T-cell Therapy Market Categorization: Regional Estimates & Trend Analysis, by Use-type & Therapy Type7.1 T-cell Therapy Market Share by Regional, 2018 & 20267.2 North America7.3 Europe7.4 Asia Pacific7.5 Latin America7.6 MEA

Chapter 8 Competitive Landscape8.1 Strategy Framework8.2 Company Profiles8.2.1 Novartis AG8.2.2 Gilead Sciences8.2.3 bluebird bio, Inc.8.2.4 TCR2 Therapeutics Inc.8.2.5 Sorrento Therapeutics8.2.6 Fate Therapeutics8.2.7 Merck KGaA8.2.8 Pfizer Inc.8.2.9 Amgen8.2.10 Celgene Corporation

For more information about this report visit https://www.researchandmarkets.com/r/j88hyn

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original:
Global T-Cell Therapy Market: Trends, Opportunities and Forecasts (2019-2026) - Therapy for Solid Tumors Expected to Emerge as a Lucrative Source of...